These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 18978532

  • 1. New strategies for control of respiratory syncytial virus infection.
    Nokes JD, Cane PA.
    Curr Opin Infect Dis; 2008 Dec; 21(6):639-43. PubMed ID: 18978532
    [Abstract] [Full Text] [Related]

  • 2. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.
    Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.
    J Mol Biol; 2007 May 04; 368(3):652-65. PubMed ID: 17362988
    [Abstract] [Full Text] [Related]

  • 3. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA, Cosgrove JF, MacMahon P.
    Ir Med J; 2000 Dec 04; 93(9):284. PubMed ID: 11209917
    [Abstract] [Full Text] [Related]

  • 4. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR.
    Expert Rev Anti Infect Ther; 2011 Jan 04; 9(1):27-32. PubMed ID: 21171875
    [Abstract] [Full Text] [Related]

  • 5. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.
    Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL.
    J Infect Dis; 2005 Apr 01; 191(7):1093-104. PubMed ID: 15747245
    [Abstract] [Full Text] [Related]

  • 6. Respiratory syncytial virus infections: characteristics and treatment.
    Chidgey SM, Broadley KJ.
    J Pharm Pharmacol; 2005 Nov 01; 57(11):1371-81. PubMed ID: 16259768
    [Abstract] [Full Text] [Related]

  • 7. Motavizumab, a second-generation humanized mAb for the prevention of respiratory syncytial virus infection in high-risk populations.
    Weisman LE.
    Curr Opin Mol Ther; 2009 Apr 01; 11(2):208-18. PubMed ID: 19330726
    [Abstract] [Full Text] [Related]

  • 8. [Anti RS virus drugs].
    Suzumura H.
    Nihon Rinsho; 2012 Apr 01; 70(4):574-8. PubMed ID: 22568137
    [Abstract] [Full Text] [Related]

  • 9. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats.
    Zhao X, Chen FP, Sullender WM.
    Virology; 2004 Jan 20; 318(2):608-12. PubMed ID: 14972528
    [Abstract] [Full Text] [Related]

  • 10. New drugs and treatment for respiratory syncytial virus.
    Maggon K, Barik S.
    Rev Med Virol; 2004 Jan 20; 14(3):149-68. PubMed ID: 15124232
    [Abstract] [Full Text] [Related]

  • 11. [Humanized respiratory syncytial virus monoclonal antibody].
    Tsutsumi H.
    Nihon Rinsho; 2002 Mar 20; 60(3):487-91. PubMed ID: 11904963
    [Abstract] [Full Text] [Related]

  • 12. Prevention and treatment of respiratory syncytial virus infection in infants: an update.
    Venkatesh MP, Weisman LE.
    Expert Rev Vaccines; 2006 Apr 20; 5(2):261-8. PubMed ID: 16608425
    [Abstract] [Full Text] [Related]

  • 13. The future of respiratory syncytial virus vaccine development.
    Polack FP, Karron RA.
    Pediatr Infect Dis J; 2004 Jan 20; 23(1 Suppl):S65-73. PubMed ID: 14730272
    [Abstract] [Full Text] [Related]

  • 14. Respiratory syncytial virus infections: recent prospects for control.
    Sidwell RW, Barnard DL.
    Antiviral Res; 2006 Sep 20; 71(2-3):379-90. PubMed ID: 16806515
    [Abstract] [Full Text] [Related]

  • 15. A review of palivizumab and emerging therapies for respiratory syncytial virus.
    Shadman KA, Wald ER.
    Expert Opin Biol Ther; 2011 Nov 20; 11(11):1455-67. PubMed ID: 21831008
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats.
    Wyde PR, Moore DK, Hepburn T, Silverman CL, Porter TG, Gross M, Taylor G, Demuth SG, Dillon SB.
    Pediatr Res; 1995 Oct 20; 38(4):543-50. PubMed ID: 8559607
    [Abstract] [Full Text] [Related]

  • 17. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
    Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, Fries LF, Smith GE, Glenn GM.
    Vaccine; 2014 Nov 12; 32(48):6485-92. PubMed ID: 25269094
    [Abstract] [Full Text] [Related]

  • 18. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR, Hoopes JM, Hemming VG.
    Adv Ther; 2011 Feb 12; 28(2):110-25. PubMed ID: 21318605
    [Abstract] [Full Text] [Related]

  • 19. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 12; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 20. Translational sciences approach to RSV vaccine development.
    Kurzweil V, Tang R, Galinski M, Wang K, Zuo F, Cherukuri A, Gasser RA, Malkin E, Sifakis F, Mendel DB, Esser MT.
    Expert Rev Vaccines; 2013 Sep 12; 12(9):1047-60. PubMed ID: 24053398
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.